BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32921965)

  • 1. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
    Meo SA; Zaidi SZA; Shang T; Zhang JY; Al-Khlaiwi T; Bukhari IA; Akram J; Klonoff DC
    J King Saud Univ Sci; 2020 Oct; 32(7):3159-3166. PubMed ID: 32921965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
    Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
    Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM
    Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review.
    Mehraeen E; Najafi Z; Hayati B; Javaherian M; Rahimi S; Dadras O; SeyedAlinaghi S; Ghadimi M; Sabatier JM
    Infect Disord Drug Targets; 2022; 22(1):e260721194968. PubMed ID: 34313204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19.
    Kaur A; Chaudhary G; Singh P; Arora S; Kaur R
    Curr Drug Targets; 2021; 22(13):1536-1547. PubMed ID: 33371833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    Shah S; Das S; Jain A; Misra DP; Negi VS
    Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
    Doyno C; Sobieraj DM; Baker WL
    Clin Toxicol (Phila); 2021 Jan; 59(1):12-23. PubMed ID: 32960100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.
    Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M
    J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
    Subramanian K; Nalli A; Senthil V; Jain S; Nayak A; Bhat A
    Adv Ther; 2020 Oct; 37(10):4107-4131. PubMed ID: 32809210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.